The BioHub: The Top Voices in Biotech

We were delighted to welcome Jason Ehrlich, Co-Founder and CEO of Ollin Biosciences onto the BioHub. Ollin are a clinical-stage biotechnology company focused on advancing next-generation therapies form serious eye diseases, including wet age-related macular degeneration anddiabetic macular edema.
Before launching Ollin, Jason served as Chief MedicalOfficer and Chief Development Officer at Kodiak Sciences, where he led clinical development in retinal disease. Earlier in his career, he held senior leadership roles at Genentech, one of the pioneers in biologic medicines, helping advance therapies that have transformed care for patients with vision-threatening conditions.
Trained as both a physician and a scientist, Jason brings arare blend of clinical insight, translational research expertise, and strategic leadership. His career sits at the intersection of medicine, innovation, and company building — with a clear focus: delivering meaningful, durable therapies to patients who risk losing their sight.

In this episode of The BioHub, I’m joined by Dr. Adam Mendelsohn, Co-Founder and CEO of Vivani Medical.

Adam’s journey spans bioengineering at UCSF and UC Berkeley to founding Nano Precision Medical and now leading Vivani following its 2022 merger. Vivani is developing long-term, sub-dermal drug implants designed to transform treatment for chronic diseases such as obesity and diabetes.

We discuss the science behind the platform, why long-acting implants could shift the treatment paradigm, what’s happening at Vivani right now, and what it takes to build and finance a biotech company in today’s market.

🎙 New Episode Live – Todd Zavodnick, CEO of Excellergy
Todd Zavodnick is the CEO of Excellergy, a clinical-stage biotechnology company redefining allergy treatment. Their mission? To make therapies faster, more effective, and far more convenient for patients — transforming the experience of managing allergies.
Before Excellergy, Todd built a track record of leadership in biotech, bringing together scientific rigor and strategic vision to tackle complex challenges in patient care.
In this episode, we discuss:
Excellergy’s approach to improving existing allergy therapies and what sets them apart in the field.

Clinical milestones, including their Phase 1 launch in Australia and plans for Phase 2 next year.

The patient impact — how Excellergy is aiming to reduce wait times and make treatment truly transformative.

Whether you’re interested in biotech innovation, clinical development, or patient-centric therapies, this conversation is packed with insight.

Today’s guest is Terry J. Rosen, a scientist-entrepreneur who has helped shape the modern era of cancer immunotherapy.
Dr. Rosen is the co-founder and CEO of Arcus Biosciences, a clinical-stage biotechnology company focused on developing innovative immuno-oncology therapies and combination treatments designed to transform outcomes for patients with cancer. Before launching Arcus, he co-founded Flexus Biosciences, which was acquired by Bristol-Myers Squibb in 2015—an early validation of his vision in immune-based therapies.
Across his career, Terry has held senior scientific and leadership roles at major biopharmaceutical organizations including Amgen, Pfizer, and Abbott Laboratories, building a track record that bridges rigorous medicinal chemistry with bold company creation.

In this we discuss:
Arcus' pipeline and what makes them stand out from other companies in the immuno-oncology field
What makes Arcus a compelling investment opportunity today and how they balance the long timelines and risks of drug development with the expectations of public markets and investors?
The key milestones for Arcus in the next year to18 months that the scientific and investment communities should be paying attention to

In this episode of The BioHub, I’m joined by Thijs Spoor, CEO of Perspective Therapeutics.

Thijs has taken an unconventional path to the CEO seat, bringing decades of leadership experience across healthcare and capital markets into one of the most exciting areas of biotech: targeted radiopharmaceuticals.

We talk about his journey into the industry, the science and vision behind Perspective, the company’s recent $175M raise, and the milestones that could define their next phase of growth. A great conversation about bold strategy, differentiated science, and building momentum in today’s market.